Welcome to our dedicated page for American Wtr Wks Co SEC filings (Ticker: AWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Water Works Company (AWK) keeps more than 14 million people supplied with safe, reliable water—yet the details that move its share price live deep inside SEC documents. Whether you’re tracking how new rate cases fund pipeline replacement or measuring dividend sustainability, you’ll find every disclosure right here.
Stock Titan brings AI-powered summaries to each filing, turning dense accounting tables into clear takeaways. Need to monitor American Water Works insider trading Form 4 transactions or set alerts for American Water Works Form 4 insider transactions real-time? Our platform flags each entry within seconds of EDGAR release. Reviewing the next American Water Works quarterly earnings report 10-Q filing? We map revenue by regulated state and highlight capital-expenditure variances. For long-range analysis, the American Water Works annual report 10-K simplified view extracts rate-base growth, infrastructure spend and environmental commitments—all explained in plain language.
Common questions are answered as you scroll: American Water Works 8-K material events explained pinpoints new rate approvals; American Water Works proxy statement executive compensation breaks down pay versus performance metrics; our American Water Works earnings report filing analysis compares sequential operating margins; and “understanding American Water Works SEC documents with AI” is no longer a hurdle. From dividend investors watching cash-flow coverage to ESG analysts examining lead-service line replacement, comprehensive real-time coverage means you spend minutes, not hours, extracting insight.
Enliven Therapeutics, Inc. (ELVN) – Form 4 insider transaction. Chief Financial Officer Benjamin Hohl exercised 3,250 employee stock options at an exercise price of $2.48 per share and immediately sold the same 3,250 shares under a pre-arranged Rule 10b5-1 trading plan dated 26 Jun 2023.
- Option exercise: 3,250 shares converted from options granted 2 Aug 2021 (portion of a 262,120-share grant that vests monthly through Aug 2025).
- Sales: 3,052 shares sold at a volume-weighted average price (VWAP) of $20.8609 and 198 shares at a VWAP of $21.6583; individual trade ranges were $20.58-$21.575 and $21.5811-$21.788, respectively.
- Holdings after transactions: 23,000 shares of common stock held directly and 115,806 options outstanding.
- The exercise-and-sell was executed the same day (27 Jun 2025) and disclosed 1 Jul 2025.
The transaction represents routine liquidity management by the CFO; the net economic exposure (shares plus remaining options) remains substantial.